ArticleAdvances in experimental medicine and biology2025
Current Status and Future Prospects for Cell Therapy Manufacturing at KNIH.
Article in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The National Center for Stem Cell and Regenerative Medicine (NCSR) of the Republic of Korea plays a crucial role in advancing stem cell research and clinical applications. Since its establishment, the NCSR has expanded its role not only to operate a stem cell bank but also to establish and manage facilities that comply with Good Manufacturing Practice (GMP), thereby supporting the overall development of stem cell-based therapeutics. In addition to standardizing high-quality human pluripotent stem cells for distribution to researchers, the NCSR actively engages in international collaboration to enhance the reliability of research resources. Furthermore, through the implementation of laws regarding advanced regenerative medicine and the safety and support of advanced biopharmaceuticals, the Republic of Korea has secured a leading position in the global regenerative medicine field. This paper highlights the operational achievements of the NCSR, its role in supporting clinical research, and future strategies to strengthen the development of stem cell therapeutics. The NCSR aims to promote the commercialization of advanced regenerative medicine therapeutics by enhancing GMP infrastructure and facilitating international cooperation, thereby contributing to the advancement of precision medicine and innovative healthcare solutions.
Indexed as
Identifiers
41136845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.